Literature DB >> 2065694

Long-term haemodynamic effects of sustained-release trimazosin at rest and during exercise in essential hypertension.

P Omvik1, P Lund-Johansen.   

Abstract

The long-term haemodynamic effect of sustained-release trimazosin (mean daily dose 418 mg) at rest and during exercise has been examined in 14 male patients (age 30-61 y) with previously untreated mild or moderate essential hypertension. Cardiac output (dye dilution), heart rate and intra-arterial blood pressure were measured supine and sitting at rest, and during bicycle exercise. After 11 months of trimazosin treatment the mean casual blood pressure was reduced from 165/106 mmHg to 147/92 mmHg. The intra-arterial systolic and diastolic pressure was reduced by 3-7% at rest and during 50, 100 and 150 W exercise. Total peripheral resistance was reduced by 8-14% and cardiac output was slightly higher (2-8%) in all situations. Stroke volume and heart rate remained unchanged, as did body fluid volumes (isotope dilution) and body weight. Side effects were minor and transient. Thus, the haemodynamic responses to trimazosin are similar to but weaker than those of other alpha 1-adrenoceptor blockers. The efficacy of the sustained-release formulation of trimazosin was low and daily doses above 600 mg are likely to be needed by many patients.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 2065694     DOI: 10.1007/BF00280066

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN: 0031-6970            Impact factor:   2.953


  12 in total

1.  Effect on resting blood pressure and blood pressure homeostasis of short-term administration of the alpha 1-adrenergic receptor antagonist, trimazosin, in hypertension.

Authors:  L Sampieri; C Cuspidi; L Boselli; L Angioni; G Castiglioni; A Zanchetti; G Mancia
Journal:  Cardiovasc Drugs Ther       Date:  1988-01       Impact factor: 3.727

2.  Pharmacokinetics of a sustained-release trimazosin tablet formulation.

Authors:  B Flouvat; F Fodor; A Roux; J R Bianchine
Journal:  Am Heart J       Date:  1983-11       Impact factor: 4.749

3.  The cardiovascular effects of trimazosin.

Authors:  J W Constantine; H J Hess
Journal:  Eur J Pharmacol       Date:  1981-09-11       Impact factor: 4.432

4.  Pharmacokinetics and pharmacodynamics of trimazosin in man.

Authors:  J L Reid; P A Meredith; H L Elliott
Journal:  Am Heart J       Date:  1983-11       Impact factor: 4.749

5.  Comparison of trimazosin and methyldopa in hypertension.

Authors:  W S Aronow; J Tobis; D Hughes; J Siegel; J Easthope
Journal:  Clin Pharmacol Ther       Date:  1977-10       Impact factor: 6.875

6.  Profile of trimazosin: an effective and safe antihypertensive agent.

Authors:  C R Taylor; J P Leader; W Singleton; E W Munster; F C Falkner; J A O'Neil
Journal:  Am Heart J       Date:  1983-11       Impact factor: 4.749

7.  Clinical hemodynamic profile of trimazosin in hypertension.

Authors:  P E Pool; S C Seagren; A F Salel
Journal:  Am Heart J       Date:  1983-11       Impact factor: 4.749

8.  Autonomic, systemic, and renal hemodynamic actions of trimazosin in hypertensive patients.

Authors:  S G Chrysant
Journal:  Am Heart J       Date:  1983-11       Impact factor: 4.749

9.  Double-blind comparison of trimazosin and propranolol in essential hypertension.

Authors:  A Helgeland
Journal:  Am Heart J       Date:  1983-11       Impact factor: 4.749

Review 10.  Prazosin update. A review of its pharmacological properties and therapeutic use in hypertension and congestive heart failure.

Authors:  W F Stanaszek; D Kellerman; R N Brogden; J A Romankiewicz
Journal:  Drugs       Date:  1983-04       Impact factor: 9.546

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.